Sensus Healthcare Plunges 34% on Revenue Miss and Lower Sales
Sensus Healthcare, Inc. (SRTS) dropped 33.55%, leading losses in the PRISM Emerging MedDevices Index, after reporting Q2 revenue of $7.3M, down from $9.2M a year earlier. While the company saw a 27% sequential increase in FDA treatment volume and shipped 19 superficial radiotherapy systems, sales momentum in the U.S. was dampened by a proposed reimbursement change for ultrasound use with its SRT-100 Vision™ system. Gross margin also fell to 39.7% from 58.7% in the prior-year quarter, and adjusted EBITDA turned negative at $(1.8)M. Management highlighted the recent MDSAP certification and a new distribution partnership with Radiology Oncology Systems as strategic steps toward future growth, with potential Medicare reimbursement improvements expected in 2026.
OptimizeRx Jumps 30% on Blowout Quarter and Raised Guidance
OptimizeRx Corporation (OPRX) climbed 29.58%, boosting the PRISM Emerging Healthcare Index, after reporting a 55% year-over-year revenue jump to $29.2M and a 59% surge in gross profit to $18.6M. GAAP net income swung to $1.5M from a $4.0M loss last year, while adjusted EBITDA soared to $5.8M from $0.5M. The company credited growth to strong adoption of its AI-driven patient finding technology, deeper pharmaceutical partnerships, and disciplined operational execution. Management also raised its full-year revenue guidance to $104M–$108M and adjusted EBITDA outlook to $14.5M–$17.5M, while accelerating debt repayment with $4.5M paid down in Q2.
Other PRISM Mid-Day Movers:
• BioXcel Therapeutics, Inc. (BTAI) up 33.40%
• Owlet, Inc. (OWLT) up 22.28%
• Canopy Growth Corporation (CGC) up 22.38
The post PRISM Mid-Day Movers: MedDevice Setback and Healthcare Tech Surge appeared first on PRISM MarketView.
